Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208169 · ClinicalTrials.gov registry record · Phase 4
Abilify Therapy for Reducing Comorbid Substance Abuse
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00208169 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 30 participants.
The verdict
NCT00208169, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: * Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) * Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale * Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208169
The ClinicalTrials.gov registry entry for NCT00208169 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00208169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208169 about?
NCT00208169 is a clinical study titled "Abilify Therapy for Reducing Comorbid Substance Abuse". It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: * Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) ...
What is the current status of trial NCT00208169?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2005-03. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00208169?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00208169?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.